Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Dangers of HAVA

This is 18,000 patients in the USU. Like most of these rare diseases, unfortunately, it's awful. Every time I look at one of these, I'm always just like, oh my god, I'm so glad I don't have... It's terrible. The way that this disease is treated today is with a jack inhibitor called jackify from insight. So all the drugs that are being tested for mild fibrosis are all trying to do what Jack-ify does better.

Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner